The MMRC is a cutting-edge collaborative research model that brings together a network of academic research institutions with partners in the biotech and pharmaceutical industries to conduct Phase 1 and Phase 2 clinical trials of novel compounds and combination therapies for multiple myeloma.
Over the years we have worked with dozens of companies to support a diverse and balanced portfolio of compounds, including next-generation and novel compounds from multiple drug classes. Importantly, we do not offer target exclusively – our focus is on advancing the most promising new agents.
As a trusted third party, our model aims to de-risk each step along the drug development pathway by promoting efficiency, speed, and results through innovative business solutions.
Our partners include established companies in the field such as Celgene, Millennium Pharmaceuticals, and Novartis; new ones such as Onyx Pharmaceuticals; and a number of emerging biotech companies such as Array, Astex, and Synta.
Our track record speaks for itself. To date we have spearheaded the launch of more than 40 clinical trials – with recent ones opening 60% faster that comparable oncology clinical trials.
For more information, contact Walter Capone at firstname.lastname@example.org or 203-652-0202.